About Oncology AI Fleet
Oncology AI Fleet makes AI-driven clinical documentation software for specialty oncology clinics. The platform pairs a real-time CDI Intelligence Engine with an Analytics Dashboard that works at the population level.
The company is a Delaware C-corporation formed in 2026 and based in Lewes, Delaware. Phyllis Mullen is the founder and chief executive officer. She has more than 20 years of experience in clinical documentation, oncology workflows and AI-assisted medical transcription.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Not yet | Oct 28, 2026 | $0of $500K target | 0 | — | Simple Agreement for Future Equity (SAFE)Rule 506(c) | Form D ↗ |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed Oncology AI Fleet
Oncology AI Fleet sells clinical documentation software to specialty oncology clinics. Phyllis Mullen founded the company in 2026 after more than 20 years in oncology documentation work. The company is at an early stage and is raising a pre-seed round.
The problem it targets
Oncology AI Fleet points to the documentation demands of specialty oncology practice, from the infusion chair to the tumor board. Its stated aim is to cut the cognitive load of that work at every step.
What the product does
The platform covers the documentation journey from intake to survivorship. A FHIR R4 data spine links the real-time engine and the analytics dashboard. Clinical safety and regulatory alignment are named as design priorities.
Progress so far
The company was formed as a Delaware C-corporation in 2026. It works with clinical advisors who contribute insights on AI workflows, clinical documentation patterns and emerging healthcare technologies. The company has not named customers.
Who backs it
The company has not named an investor. It is raising a pre-seed round, and its site invites investor inquiries.
We wrote this summary from public statements by Oncology AI Fleet and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on Oncology AI Fleet's Form D filed Oct 28, 2026.